v3.10.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Revenues $ 45 $ 122
Operating expenses:    
Research and development (related parties of $259 and $176), net of $0 and $44 in grant income 1,124 985
General and administrative (related parties of $261 and $206) 2,871 2,498
Total operating expenses 3,995 3,483
Operating loss (3,950) (3,361)
Other income (expense):    
Interest expense (related party of $476 and $480) (476) (480)
Interest income 21 5
Royalty income 6 9
Total other income (expense) (449) (466)
Consolidated net loss (4,399) (3,827)
Net loss attributable to noncontrolling interest 1 1
Net loss attributable to iBio, Inc. (4,398) (3,826)
Preferred stock dividends (66) (66)
Net loss available to iBio, Inc. (4,464) (3,892)
Comprehensive loss:    
Consolidated net loss (4,399) (3,827)
Other comprehensive loss - foreign currency translation adjustments (1) 0
Comprehensive loss $ (4,400) $ (3,827)
Loss per common share attributable to iBio, Inc. stockholders – basic and diluted $ (0.25) $ (0.42)
Weighted-average common shares outstanding – basic and diluted 17,894 9,185

Source